Cargando…
Gadolinium Neutron Capture Therapy (GdNCT) Agents from Molecular to Nano: Current Status and Perspectives
[Image: see text] (157)Gd (natural abundance = 15.7%) has the highest thermal neutron capture cross section (σ) of 254,000 barns (1 barn = 10(–28) m(2)) among stable (nonradioactive) isotopes in the periodic table. Another stable isotope, (155)Gd (natural abundance = 14.8%), also has a high σ value...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793081/ https://www.ncbi.nlm.nih.gov/pubmed/35097254 http://dx.doi.org/10.1021/acsomega.1c06603 |
_version_ | 1784640518989283328 |
---|---|
author | Ho, Son Long Yue, Huan Tegafaw, Tirusew Ahmad, Mohammad Yaseen Liu, Shuwen Nam, Sung-Wook Chang, Yongmin Lee, Gang Ho |
author_facet | Ho, Son Long Yue, Huan Tegafaw, Tirusew Ahmad, Mohammad Yaseen Liu, Shuwen Nam, Sung-Wook Chang, Yongmin Lee, Gang Ho |
author_sort | Ho, Son Long |
collection | PubMed |
description | [Image: see text] (157)Gd (natural abundance = 15.7%) has the highest thermal neutron capture cross section (σ) of 254,000 barns (1 barn = 10(–28) m(2)) among stable (nonradioactive) isotopes in the periodic table. Another stable isotope, (155)Gd (natural abundance = 14.8%), also has a high σ value of 60,700 barns. These σ values are higher than that of (10)B (3840 barns, natural abundance = 19.9%), which is currently used as a neutron-absorbing isotope for boron neutron capture therapy agents. Energetic particles such as electrons and γ-rays emitted from Gd-isotopes after neutron beam absorption kill cancer cells by damaging DNAs inside cancer-cell nuclei without damaging normal cells if Gd-chemicals are positioned in cancer cells. To date, various Gd-chemicals such as commercial Gd-chelates used as magnetic resonance imaging contrast agents, modified Gd-chelates, nanocomposites containing Gd-chelates, fullerenes containing Gd, and solid-state Gd-nanoparticles have been investigated as gadolinium neutron capture therapy (GdNCT) agents. All GdNCT agents had exhibited cancer-cell killing effects, and the degree of the effects depended on the GdNCT agents used. This confirms that GdNCT is a promising cancer therapeutic technique. However, the commercial Gd-chelates were observed to be inadequate in clinical use because of their low accumulation in cancer cells due to their extracellular and noncancer targeting properties and rapid excretion. The other GdNCT agents exhibited higher accumulation in cancer cells, compared to Gd-chelates; consequently, they demonstrated higher cancer-cell killing effects. However, they still displayed limitations such as poor specificity to cancer cells. Therefore, continuous efforts should be made to synthesize GdNCT agents suitable in clinical applications. Herein, the principle of GdNCT, current status of GdNCT agents, and general design strategy for GdNCT agents in clinical use are discussed and reviewed. |
format | Online Article Text |
id | pubmed-8793081 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-87930812022-01-28 Gadolinium Neutron Capture Therapy (GdNCT) Agents from Molecular to Nano: Current Status and Perspectives Ho, Son Long Yue, Huan Tegafaw, Tirusew Ahmad, Mohammad Yaseen Liu, Shuwen Nam, Sung-Wook Chang, Yongmin Lee, Gang Ho ACS Omega [Image: see text] (157)Gd (natural abundance = 15.7%) has the highest thermal neutron capture cross section (σ) of 254,000 barns (1 barn = 10(–28) m(2)) among stable (nonradioactive) isotopes in the periodic table. Another stable isotope, (155)Gd (natural abundance = 14.8%), also has a high σ value of 60,700 barns. These σ values are higher than that of (10)B (3840 barns, natural abundance = 19.9%), which is currently used as a neutron-absorbing isotope for boron neutron capture therapy agents. Energetic particles such as electrons and γ-rays emitted from Gd-isotopes after neutron beam absorption kill cancer cells by damaging DNAs inside cancer-cell nuclei without damaging normal cells if Gd-chemicals are positioned in cancer cells. To date, various Gd-chemicals such as commercial Gd-chelates used as magnetic resonance imaging contrast agents, modified Gd-chelates, nanocomposites containing Gd-chelates, fullerenes containing Gd, and solid-state Gd-nanoparticles have been investigated as gadolinium neutron capture therapy (GdNCT) agents. All GdNCT agents had exhibited cancer-cell killing effects, and the degree of the effects depended on the GdNCT agents used. This confirms that GdNCT is a promising cancer therapeutic technique. However, the commercial Gd-chelates were observed to be inadequate in clinical use because of their low accumulation in cancer cells due to their extracellular and noncancer targeting properties and rapid excretion. The other GdNCT agents exhibited higher accumulation in cancer cells, compared to Gd-chelates; consequently, they demonstrated higher cancer-cell killing effects. However, they still displayed limitations such as poor specificity to cancer cells. Therefore, continuous efforts should be made to synthesize GdNCT agents suitable in clinical applications. Herein, the principle of GdNCT, current status of GdNCT agents, and general design strategy for GdNCT agents in clinical use are discussed and reviewed. American Chemical Society 2022-01-12 /pmc/articles/PMC8793081/ /pubmed/35097254 http://dx.doi.org/10.1021/acsomega.1c06603 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Ho, Son Long Yue, Huan Tegafaw, Tirusew Ahmad, Mohammad Yaseen Liu, Shuwen Nam, Sung-Wook Chang, Yongmin Lee, Gang Ho Gadolinium Neutron Capture Therapy (GdNCT) Agents from Molecular to Nano: Current Status and Perspectives |
title | Gadolinium Neutron Capture Therapy (GdNCT) Agents
from Molecular to Nano: Current Status and Perspectives |
title_full | Gadolinium Neutron Capture Therapy (GdNCT) Agents
from Molecular to Nano: Current Status and Perspectives |
title_fullStr | Gadolinium Neutron Capture Therapy (GdNCT) Agents
from Molecular to Nano: Current Status and Perspectives |
title_full_unstemmed | Gadolinium Neutron Capture Therapy (GdNCT) Agents
from Molecular to Nano: Current Status and Perspectives |
title_short | Gadolinium Neutron Capture Therapy (GdNCT) Agents
from Molecular to Nano: Current Status and Perspectives |
title_sort | gadolinium neutron capture therapy (gdnct) agents
from molecular to nano: current status and perspectives |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793081/ https://www.ncbi.nlm.nih.gov/pubmed/35097254 http://dx.doi.org/10.1021/acsomega.1c06603 |
work_keys_str_mv | AT hosonlong gadoliniumneutroncapturetherapygdnctagentsfrommoleculartonanocurrentstatusandperspectives AT yuehuan gadoliniumneutroncapturetherapygdnctagentsfrommoleculartonanocurrentstatusandperspectives AT tegafawtirusew gadoliniumneutroncapturetherapygdnctagentsfrommoleculartonanocurrentstatusandperspectives AT ahmadmohammadyaseen gadoliniumneutroncapturetherapygdnctagentsfrommoleculartonanocurrentstatusandperspectives AT liushuwen gadoliniumneutroncapturetherapygdnctagentsfrommoleculartonanocurrentstatusandperspectives AT namsungwook gadoliniumneutroncapturetherapygdnctagentsfrommoleculartonanocurrentstatusandperspectives AT changyongmin gadoliniumneutroncapturetherapygdnctagentsfrommoleculartonanocurrentstatusandperspectives AT leegangho gadoliniumneutroncapturetherapygdnctagentsfrommoleculartonanocurrentstatusandperspectives |